StreetInsider.com News Articles

CytomX Therapeutics (CTMX) PT Lowered to $14 at Guggenheim

Mon, 10 Aug 2026 07:40:21 -0400

(Updated - August 10, 2026 7:40 AM EDT)

Guggenheim analyst Michael Sch lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $14.00 (from $15.00) while maintaining a Buy rating.

The analyst commented: 'CTMX reported 2Q earnings and a business update focusing predominantly on clinical progress for lead program Varseta-M (EpCAM ADC) and the planned clinical update in CRC in 2H. Management highlighted that the update will include longer follow-up for OS for the patients from the clinical update in March (here), as well as safety/efficacy data from the dose-optimization cohort (N=40) which includes AIBW dosing and enhanced prophylaxis to mitigate high-grade

CytomX Therapeutics (CTMX) PT Lowered to $14 at Guggenheim

Mon, 10 Aug 2026 07:40:21 -0400

(Updated - August 10, 2026 7:40 AM EDT)

Guggenheim analyst Michael Sch lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $14.00 (from $15.00) while maintaining a Buy rating.

Form SCHEDULE 13G CytomX Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260807/26888482.html

Form SCHEDULE 13G CytomX Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260807/26888482.html

Form S-8 CytomX Therapeutics,

Thu, 06 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260806/26884562.html

Form S-8 CytomX Therapeutics,

Thu, 06 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260806/26884562.html

CytomX Therapeutics (CTMX) Misses Q2 EPS by 1c

Thu, 06 Aug 2026 16:18:44 -0400

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.41 million versus the consensus estimate of $11.33 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 16:15:00 -0400

Varsetatug masetecan (“Varseta-M”) Program:

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 -

- Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) -

Corporate:

- Regeneron alliance in masked

Form 8-K CytomX Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260806/26884053.html

Form 8-K CytomX Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260806/26884053.html